US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Faeth Therapeutics

35.37

-3.7200-9.52%

Post-market: 35.880.5100+1.44%19:53 EDT

Volume:209.39K

Turnover:7.67M

Market Cap:911.80M

PE:-0.25

High:39.89

Open:38.75

Low:34.88

Close:39.09

52wk High:42.14

52wk Low:7.45

Shares:25.78M

Float Shares:811.70K

Volume Ratio:0.68

T/O Rate:25.80%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-141.6499

EPS(LYR):-16.7239

ROE:-195.26%

ROA:-20.79%

PB:5.27

PE(LYR):-2.11

Loading ...

Overview Company News Filings

Faeth Therapeutics - Interim Data from Phase 1B/2 Trial in Advanced Breast Cancer Expected in 2027

THOMSON REUTERS

Faeth Therapeutics Names Deepak Tiwari SVP of Technical Operations

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

THOMSON REUTERS

Faeth Therapeutics Price Target Maintained with a $60.00/Share by HC Wainwright & Co.

Faeth Therapeutics Grants New-Hire Stock Options for 11,000 Shares at $25.5 Each

Faeth Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Faeth Therapeutics Presents PK/PD Modeling Supporting Piktor Dose in Phase 2 Endometrial Cancer Trial FTH-PIK-201

Faeth Therapeutics management to meet with BTIG

Faeth Therapeutics, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Faeth Therapeutics initiated with a Buy at JonesResearch

Faeth Therapeutics, Inc : Jonestrading Initiates Coverage with Buy Rating; Target Price $55

THOMSON REUTERS

Faeth Therapeutics reports Q2 EPS ($2.84) vs ($3.91) last year

Faeth Therapeutics Q2 EPS $(2.84) Beats $(3.29) Estimate

Benzinga Earnings

Faeth Therapeutics Q2 FY26 Net Loss Widens to $16.01 Million

Press Release: Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates

U.S. Research Roundup-Cloudflare, Replimune, Walmart

Faeth Therapeutics, Inc Expected to Post a Loss of $3.62 a Share - Earnings Preview

Raymond James Initiates Faeth Therapeutics at Outperform

MT Newswires Live

Faeth Therapeutics initiated with an Outperform at Raymond James

Faeth Therapeutics Files Initial Beneficial Ownership Statement for Khosla Ventures VI, L.P

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/FTH/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FTH\",,,,,undefined,":{"symbol":"FTH","market":"US","secType":"STK","nameCN":"Faeth Therapeutics","latestPrice":35.37,"timestamp":1789502400000,"preClose":39.09,"halted":0,"volume":209394,"hourTrading":{"tag":"盘后","latestPrice":35.88,"preClose":35.37,"latestTime":"19:53 EDT","volume":358,"amount":12833.5401,"timestamp":1789516430954,"change":0.51,"changeRate":0.014419,"amplitude":0.014419},"delay":0,"changeRate":-0.09516500383729869,"floatShares":811700,"shares":25778800,"eps":-141.6499,"marketStatus":"Not Yet Opened","change":-3.72,"latestTime":"09-15 16:00:00 EDT","open":38.75,"high":39.89,"low":34.88,"amount":7666233.875244,"amplitude":0.128166,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-141.6499,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":0,"adr":0,"listingDate":1612414800000,"exchange":"NASDAQ","adjPreClose":39.09,"postHourTrading":{"tag":"盘后","latestPrice":35.88,"preClose":35.37,"latestTime":"19:53 EDT","volume":358,"amount":12833.5401,"timestamp":1789516430954,"change":0.51,"changeRate":0.014419,"amplitude":0.014419},"volumeRatio":0.675028},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FTH\",,,,,undefined,":{"symbol":"FTH","floatShares":811700,"roa":"-20.79%","roe":"-195.26%","lyrEps":-16.72388,"volumeRatio":0.675028,"shares":25778800,"dividePrice":0,"high":39.89,"amplitude":0.128166,"preClose":39.09,"low":34.88,"week52Low":7.45,"pbRate":"5.27","week52High":42.1431,"institutionHeld":0,"latestPrice":35.37,"eps":-141.6499,"divideRate":0,"volume":209394,"delay":0,"ttmEps":-141.6499,"open":38.75,"prevYearClose":10.67,"prevWeekClose":37.44,"prevMonthClose":32.77,"prevQuarterClose":25,"fiveDayClose":39.2,"twentyDayClose":32.77,"sixtyDayClose":17.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FTH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"FTH","fiscalQuarterEnding":"2026/06","expectedEps":-1.1,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"pre","actualEps":-2.84},{"market":"US","date":"2026-05-15","symbol":"FTH","fiscalQuarterEnding":"2026/03","expectedEps":-0.62,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-131.45},{"market":"US","date":"2026-03-30","symbol":"FTH","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"pre","actualEps":-3.74},{"market":"US","date":"2025-11-14","symbol":"FTH","fiscalQuarterEnding":"2025/09","expectedEps":-4.11,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"pre","actualEps":-3.62},{"market":"US","date":"2025-08-05","symbol":"FTH","fiscalQuarterEnding":"2025/06","expectedEps":-6.2,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"pre","actualEps":-3.91}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FTH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FTH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4167,"buy":0.5833,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1789012800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FTH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FTH","date":"2026-09-14","current":-0.2497,"percent":0.101695,"low":-5.292894,"twenty":-4.561008,"median":-3.985108,"eighty":-3.360395,"high":-0.105707,"avg":-3.827199,"sd":1.140745,"marketCap":967465512},"quantilePoints":[{"date":"2026-06-18","current":-0.12113,"twenty":-0.118045,"median":-0.113419,"eighty":-0.108792,"marketCap":22343317},{"date":"2026-06-26","current":-3.447751,"twenty":-3.41449,"median":-0.168709,"eighty":-0.122832,"marketCap":635961861},{"date":"2026-07-02","current":-3.306599,"twenty":-3.429583,"median":-3.245107,"eighty":-0.129642,"marketCap":609925319},{"date":"2026-07-10","current":-4.547622,"twenty":-3.49387,"median":-3.330357,"eighty":-0.168709,"marketCap":838840655},{"date":"2026-07-17","current":-3.62524,"twenty":-4.398084,"median":-3.429583,"eighty":-3.196193,"marketCap":668700878},{"date":"2026-07-24","current":-3.879594,"twenty":-4.005373,"median":-3.554664,"eighty":-3.20318,"marketCap":715618211},{"date":"2026-07-31","current":-4.027734,"twenty":-4.074133,"median":-3.637119,"eighty":-3.236722,"marketCap":742943690},{"date":"2026-08-07","current":-3.227486,"twenty":-4.048697,"median":-3.62524,"eighty":-3.239088,"marketCap":631063897},{"date":"2026-08-14","current":-3.773087,"twenty":-4.030809,"median":-3.711043,"eighty":-3.239088,"marketCap":737744133},{"date":"2026-08-21","current":-4.242245,"twenty":-4.248589,"median":-3.806921,"eighty":-3.244483,"marketCap":829477642},{"date":"2026-08-28","current":-4.458983,"twenty":-4.358015,"median":-3.881185,"eighty":-3.294301,"marketCap":871855939},{"date":"2026-09-04","current":-5.154129,"twenty":-4.410264,"median":-3.939688,"eighty":-3.344613,"marketCap":1007776575},{"date":"2026-09-11","current":-5.154129,"twenty":-4.552871,"median":-3.964844,"eighty":-3.358825,"marketCap":1007776575},{"date":"2026-09-14","current":-4.947964,"twenty":-4.561008,"median":-3.985108,"eighty":-3.360395,"marketCap":967465512}],"updateTime":1789534910771},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FTH\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660828574","title":"Faeth Therapeutics - Interim Data from Phase 1B/2 Trial in Advanced Breast Cancer Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2660828574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660828574?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:30","pubTimestamp":1786966200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA6WSPMW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145715","title":"Faeth Therapeutics Names Deepak Tiwari SVP of Technical Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145715","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145715?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:30","pubTimestamp":1786707019,"startTime":"0","endTime":"0","summary":"Faeth Therapeutics names Deepak Tiwari SVP of technical operationsFaeth Therapeutics named Deepak Tiwari senior vice president, technical operations, to oversee CMC and supply chain for the PIKTOR pro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDLbDn0P0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAX","FTH","LU2098885051.SGD","LU0006061336.USD","LU0162691827.USD","BK4139","LU0310799852.SGD","LU0072461881.USD","LU0211327993.USD","BK4504","LU0211328371.USD","LU1267930490.SGD","BK4588","BK4585","BK4082","LU1303367103.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659757145","title":"Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2659757145","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659757145?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:30","pubTimestamp":1786707000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA6MLPT4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990038","title":"Faeth Therapeutics Price Target Maintained with a $60.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990038","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990038?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:27","pubTimestamp":1786451220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FTH/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657162573","title":"Faeth Therapeutics Grants New-Hire Stock Options for 11,000 Shares at $25.5 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2657162573","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657162573?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:00","pubTimestamp":1786132815,"startTime":"0","endTime":"0","summary":"Faeth Therapeutics grants new-hire stock options for 11,000 shares at $25.5 eachFaeth Therapeutics granted options covering 11,000 common shares to two new employees under its 2026 Inducement Plan, ef","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL25KRQR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657625783","title":"Faeth Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657625783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657625783?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:00","pubTimestamp":1786132800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA2HSLQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657485136","title":"Faeth Therapeutics Presents PK/PD Modeling Supporting Piktor Dose in Phase 2 Endometrial Cancer Trial FTH-PIK-201","url":"https://stock-news.laohu8.com/highlight/detail?id=2657485136","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657485136?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:30","pubTimestamp":1786102257,"startTime":"0","endTime":"0","summary":"Faeth Therapeutics presents PK/PD modeling supporting PIKTOR dose in Phase 2 endometrial cancer trial FTH-PIK-201Faeth Therapeutics will present PK/PD modeling for its oral PI3K/AKT/mTOR inhibitor com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL94wMFZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657324568","title":"Faeth Therapeutics management to meet with BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2657324568","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657324568?lang=en_us&edition=fundamental","pubTime":"2026-08-05 00:25","pubTimestamp":1785860741,"startTime":"0","endTime":"0","summary":"Meeting to be held in Baltimore/Washington, DC on August 10 hosted by BTIG. Published first on TheFly – the ultimate source for real-time, market-m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/faeth-therapeutics-management-to-meet-with-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/faeth-therapeutics-management-to-meet-with-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656559845","title":"Faeth Therapeutics, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2656559845","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656559845?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:51","pubTimestamp":1785847879,"startTime":"0","endTime":"0","summary":"Faeth Therapeutics, Inc reports results for the quarter ended June 30 - Earnings SummaryFaeth Therapeutics, IncFTH.OQreported a quarterly adjusted loss of $2.84 per share for the quarter ended June 30","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4411L9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656155535","title":"Faeth Therapeutics initiated with a Buy at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2656155535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656155535?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:01","pubTimestamp":1785844881,"startTime":"0","endTime":"0","summary":"JonesResearch analyst Boris Peaker initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $55 price target The firm believes the comp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/faeth-therapeutics-initiated-with-a-buy-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/faeth-therapeutics-initiated-with-a-buy-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656355387","title":"Faeth Therapeutics, Inc : Jonestrading Initiates Coverage with Buy Rating; Target Price $55","url":"https://stock-news.laohu8.com/highlight/detail?id=2656355387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656355387?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:39","pubTimestamp":1785843559,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4410YC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656553636","title":"Faeth Therapeutics reports Q2 EPS ($2.84) vs ($3.91) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2656553636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656553636?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:36","pubTimestamp":1785843369,"startTime":"0","endTime":"0","summary":"“Our combination with Sensei Biotherapeutics marked an important milestone in the history of Faeth Therapeutics (FTH),” said Anand Parikh, Chief Ex...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/faeth-therapeutics-reports-q2-eps-2-84-vs-3-91-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/faeth-therapeutics-reports-q2-eps-2-84-vs-3-91-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558027","title":"Faeth Therapeutics Q2 EPS $(2.84) Beats $(3.29) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558027","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558027?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:34","pubTimestamp":1785843269,"startTime":"0","endTime":"0","summary":"Faeth Therapeutics (NASDAQ:FTH) reported quarterly losses of $(2.84) per share which beat the analyst consensus estimate of $(3.29) by 13.68 percent. This is a 27.37 percent increase over losses of $(3.91) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60901923/faeth-therapeutics-q2-eps-2-84-beats-3-29-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558290","title":"Faeth Therapeutics Q2 FY26 Net Loss Widens to $16.01 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558290","media":"Reuters","labels":["executive","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558290?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:30","pubTimestamp":1785843059,"startTime":"0","endTime":"0","summary":"Faeth Therapeutics Q2 FY26 net loss widens to $16.01 millionFaeth Therapeutics posted a net loss of $16.01 million, or $2.84 per share, for the quarter ended June 30, 2026.R&D expense more than double","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL2Pj33L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656455826","title":"Press Release: Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656455826","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656455826?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:30","pubTimestamp":1785843000,"startTime":"0","endTime":"0","summary":"--  In June, stockholders approved the conversion of the Series B preferred. stock issued in the February 2026 acquisition of Faeth Therapeutics and. --  In June, Anand Parikh, Faeth co-founder, was appointed Chairman,President and Chief Executive Officer, and Brian Stephenson, Ph.D., CFA. was appointed Chief Financial Officer. Additionally, the board was. strengthened with the addition of former FDA Commissioner Stephen M. Hahn,M.D., and Saira Ramasastry.Second Quarter 2026 Financial Results--  Cash, Cash Equivalents and Marketable Securities: Cash, cash. equivalents and marketable securities were $186.4 million as of June 30,2026, as compared to $21.2 million as of December 31, 2025.--  Research and Development Expenses (R&D): R&D expenses for the quarter. ended June 30, 2026 were $9.2 million, compared to $2.5 million for the. quarter ended June 30, 2025. The increase in R&D expenses was primarily. driven by clinical trial and manufacturing  costs supporting the. development of PIKT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2237443895.HKD","IE00BFXG1179.USD","LU2237443382.USD","LU1363072403.SGD","IE00BHPRN162.USD","LU2237443465.HKD","BK4006","LU2746668461.USD","IE00B1BXHZ80.USD","LU2237443978.SGD","FTH","BK4122","LU0170899867.USD","LU2746668974.SGD","IE00BKVL7J92.USD","LU0149725797.USD","LU0882574139.USD","LU0267386448.USD","BK4094","LU0971096721.USD","LU2237443622.USD","PIK","CMC","IE00BZ1G4Q59.USD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656387125","title":"U.S. Research Roundup-Cloudflare, Replimune, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2656387125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656387125?lang=en_us&edition=fundamental","pubTime":"2026-08-04 15:22","pubTimestamp":1785828137,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Cloudflare, Replimune, WalmartAug 4 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cloudflare, Repl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4410IM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOW","APG","BWXT","DXCM","AN","ECHO","ARCB","HELX","WCBR","FBLG","LIFE","ABG","AMRC","IDU","CRWV","ITB","CRS","CLX","FICO","NETG","ARXS","ALHC","AVA","ALNY","BLZE","CI","CMG","DHI","FTH","EVER","AGCO","AZO","AEIS","DDOG","ADPT","SMRF","VPU","FBNC","EKG","BNY","CNC","CEG","BBY","CBOE","DUOL","NET","IVEP","UPW","NLR","CRWU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655364363","title":"Faeth Therapeutics, Inc Expected to Post a Loss of $3.62 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2655364363","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655364363?lang=en_us&edition=fundamental","pubTime":"2026-07-31 21:43","pubTimestamp":1785505401,"startTime":"0","endTime":"0","summary":"Faeth Therapeutics, Inc <FTH.OQ> expected to post a loss of $3.62 a share - Earnings PreviewFaeth Therapeutics, IncFTH.OQFTH.Ois expected to  show no change in quarterly revenue when it reports  resul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL8N43X22X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655687933","title":"Raymond James Initiates Faeth Therapeutics at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2655687933","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655687933?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:10","pubTimestamp":1785496228,"startTime":"0","endTime":"0","summary":"Faeth Therapeutics (FTH) has an average rating of buy and mean price target of $54.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FTH","RJF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655235716","title":"Faeth Therapeutics initiated with an Outperform at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2655235716","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655235716?lang=en_us&edition=fundamental","pubTime":"2026-07-31 18:10","pubTimestamp":1785492624,"startTime":"0","endTime":"0","summary":"Raymond James initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $56 price target The firm’s thesis centers on PIKTOR’s p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/faeth-therapeutics-initiated-with-an-outperform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/faeth-therapeutics-initiated-with-an-outperform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RJF","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655806148","title":"Faeth Therapeutics Files Initial Beneficial Ownership Statement for Khosla Ventures VI, L.P","url":"https://stock-news.laohu8.com/highlight/detail?id=2655806148","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655806148?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:15","pubTimestamp":1785269755,"startTime":"0","endTime":"0","summary":"Faeth Therapeutics files initial beneficial ownership statement for Khosla Ventures VI, L.PFaeth Therapeutics Form 3 filing disclosed Khosla Ventures VI as a 10% owner, reporting 2,632,232 shares of c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL3ndSHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":88,"code":"91000000","status":"200"}]}}